asundexian

Mechanism of action

• activated factor XI inhibitor, factor XIa inhibitor

Clinical trials

• among patients with atrial fibrillation at risk for stroke, asundexian 50 mg PO QD was associated with a higher incidence of stroke or systemic embolism than apixaban with 155 day prior to prematurely stopping the trial
  • fewer major bleeding events occurred with asundexian than with apixaban

More general terms

• direct oral anticoagulant; novel oral anticoagulant (DOAC, NOAC)